A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.

Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/28349

Title:	A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.
Authors:	Marcellin, P. Lau, G. Bonino, F. Farci, P. Hadziyannis, S. Jin, R. Lu, Z. Piratvisuth, T. Germanidis, G. Yurdaydın, C. Diago, M. Lai, M. Button, P. Pluck, N. Uludağ Üniversitesi/Tıp Fakültesi. Gürel, S. AAH-5364-2019 ABI-3764-2020
Keywords:	Gastroenterology & hepatology
Issue Date:	Oct-2003
Publisher:	Wiley
Citation:	Marcellin, P. vd. (2003). “A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B”. Hepatology, 38(4), Supplement 1, 724A-725A.
Description:	Bu çalışma, 24-28 Ekim 2003 tarihleri arasında Boston, Massachusetts[Amerika Birleşik Devletleri]’nde düzenlenen 5. Annual Meeting of the Federation’da bildiri olarak sunulmuştur.
URI:	http://hdl.handle.net/11452/28349
ISSN:	0270-9139
Appears in Collections:	Web of Science

Files in This Item:

There are no files associated with this item.

DSpace JSPUI